The results of the Phase III V940-001/INTerpath-001 trial mark a major milestone in cancer immunotherapy and a pivotal moment for the field of cancer vaccines.

Intismeran autogene (V940) is an investigational, personalised mRNA-based neoantigen therapy designed using each patient’s individual tumour mutations to stimulate a targeted immune response against cancer cells.

For the first time, a personalised mRNA-based cancer therapy has demonstrated positive Phase III results, meeting the primary endpoint of recurrence-free survival in patients with resected melanoma when combined with pembrolizumab.

Why is this so important?

• Personalisation: tailoring treatment to the unique mutational profile of each patient’s tumour.
• A new therapeutic strategy: harnessing mRNA technology to direct the immune system against tumour-specific neoantigens.
• Beyond melanoma: this approach could pave the way for personalised cancer vaccines across multiple tumour types.

The full results presented at ESMO 2026 will be key to understanding the magnitude of benefit and the potential clinical role of this strategy.

At GÉTICA, we believe this represents an exciting milestone in the evolution of cancer immunotherapy and a promising step towards a more personalised approach to cancer treatment.